Home Choncept is a biotech company focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products. Chondroitin produced by the gene patented by Choncept is unsulfated which can be sulfated to produce chondroitin similar to that isolated from animal sources. The unsulfated chondroitin may also be of interest as a biomaterial. Chondroitin produced recombinantly may be significantly less expensive to produce than current methods that rely on animal by-products. Modified chondroitin, dermatan sulfate, has properties as an anti-coagulant, an important pharmaceutical market.